OXYMETAZOLINE HYDROCHLORIDE

D11AX27(WHO)R01AA05(WHO),R01AB07(WHO) (combinations),S01GA04(WHO) UK:General sales list(GSL, OTC)US:OTC/ Rx-only 3-(4,5-Dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol 1491-59-4Y 4636 124 DB00935Y 4475Y 8VLN5B44ZY D08322Y CHEBI:7862Y ChEMBL762Y J5C (PDBe,RCSB PDB) DTXSID3040691 Interactive image Oc1c(c(c(cc1C(C)(C)C)C)CC/2=N/CCN\2)C InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)YKey:WYWIFABBXFUGLM-UHFFFAOYSA-NY Oxymetazoline, sold under the brand nameAfrinamong others, is atopical decongestantandvasoconstrictormedication.‍‍‍‍‍‍​​​‍​​​​​​ It is availableover-the-counteras anasal sprayto treatnasal congestionandnosebleeds, as eye drops to treat eye redness due to minor irritation, and (in the United States) as a prescription topical cream to treat persistent facial redness due torosaceain adults. Its effects begin within minutes and last for up to six hours. Intranasal use for longer than three to five days may causecongestion to recur or worsen, resulting inphysical dependence.Fluticasone propionate(Flonase) and other intranasalglucocorticoidsare known to treat oxymetazoline dependence. Oxymetazoline is a derivative ofimidazole.It was developed fromxylometazolineatMerckby Wolfgang Fruhstorfer and Helmut Müller-Calgan in 1961.A directsympathomimetic, oxymetazoline binds to and activatesα1adrenergic receptorsandα2adrenergic receptors, most notably. In 2022, it was the 305th most commonly prescribed medication in the United States, with more than 300,000 prescriptions.